Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology company has $462.6 million in cash and equivalents, enough runway to fund ...
Scouts will have their eyes peeled to see which players run the fastest, jump the highest and move the quickest at the NFL Combine. But for some evaluators, it is all about strength. One of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results